BioNTech SE (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages

BioNTech SE (NASDAQ:BNTX) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $142.72.

A number of research firms have recently issued reports on BNTX. TD Cowen cut their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Berenberg Bank initiated coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research report on Monday, November 18th. Finally, HSBC lifted their target price on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th.

Institutional Investors Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently made changes to their positions in BNTX. Daiwa Securities Group Inc. grew its position in BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after buying an additional 1,562 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of BioNTech during the 2nd quarter worth $1,586,000. Discovery Capital Management LLC CT bought a new position in shares of BioNTech in the second quarter worth $2,467,000. Marshall Wace LLP bought a new position in shares of BioNTech in the second quarter worth $2,892,000. Finally, Point72 Asset Management L.P. raised its stake in BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after purchasing an additional 341,311 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Stock Performance

NASDAQ BNTX opened at $113.67 on Thursday. The firm’s fifty day moving average price is $114.42 and its two-hundred day moving average price is $104.05. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a market capitalization of $27.25 billion, a P/E ratio of -54.13 and a beta of 0.18. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the prior year, the firm earned $0.73 EPS. BioNTech’s quarterly revenue was up 38.9% compared to the same quarter last year. As a group, research analysts anticipate that BioNTech will post -3.72 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.